Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management, discussed what evidence they believe could persuade payers to include biosimilars as preferred formulary products.
Rebecca Borgert, PharmD, BCOP, is the senior director of oncology clinical strategy and innovation and Jim Rebello, PharmD, is the vice president of formulary strategies at Magellan Rx Management.
Transcript:
What sort of evidence might help persuade payers to put more biosimilars on formulary and give them preferred status?
Borgert: That’s what we’re hoping our case study will show when we present at AMCP 2021 on Friday. We feel like we have a pretty persuasive argument that the payers that do not prefer biosimilars and instead have them just on the formulary at parity with the reference products are definitely leaving money on the table. I think if anything will motivate payers to rethink their strategy around biosimilars, I think that will be it.
Rebello: Yeah, totally agree. Case studies and data showing both the uptake and the actual savings instead of theoretical savings—having real-world savings—I think it’s great. Also, showing that the level of provider uptake and embracement that we haven’t had, because of the proactiveness and the level of collaboration, a lot of provider pushback. There has been a lot of noise. So, I think sharing all of that information with payers that maybe haven’t gone down this road yet should encourage more use, not just in oncology, but in any future biosimilar category. We know there’s more coming, probably every year for who knows how long.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More